drugset / Trial / NCT00637572
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
Phase 2
Completed
63 enrolled
Endo USA Inc., a Keenova Therapeutics Company
Quintiles, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
Timeline
- Start
- 2004-12
- Primary completion
- 2005-06
- Completion
- 2005-06
Publications
- Results Wanke C; Gutierrez J; Kristensen A; MacEarchern L. Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States. J Applied Res 2007;7(3):206-216
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 575 mg | Oral |
| Subject | Megestrol Acetate | Other / unclassified | 800 mg | Oral |